Oppenheimer Issues Positive Forecast for AtriCure (NASDAQ:ATRC) Stock Price

AtriCure (NASDAQ:ATRC) had its price target increased by Oppenheimer from $36.00 to $45.00 in a research note issued to investors on Thursday,Benzinga reports. They currently have an outperform rating on the medical device company’s stock.

A number of other research firms have also recently issued reports on ATRC. Stifel Nicolaus raised their target price on AtriCure from $36.00 to $48.00 and gave the company a “buy” rating in a research note on Thursday. JMP Securities reaffirmed a “market outperform” rating and issued a $60.00 price objective on shares of AtriCure in a report on Monday, February 10th. UBS Group boosted their target price on shares of AtriCure from $35.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. Needham & Company LLC reissued a “buy” rating and issued a $51.00 price target on shares of AtriCure in a research note on Thursday. Finally, JPMorgan Chase & Co. raised their price objective on shares of AtriCure from $40.00 to $51.00 and gave the company an “overweight” rating in a research note on Tuesday, February 11th. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $51.56.

AtriCure Stock Up 3.4 %

Shares of AtriCure stock opened at $40.94 on Thursday. The stock has a market capitalization of $2.00 billion, a price-to-earnings ratio of -49.33 and a beta of 1.46. AtriCure has a twelve month low of $18.94 and a twelve month high of $43.11. The company has a current ratio of 3.62, a quick ratio of 2.59 and a debt-to-equity ratio of 0.13. The business’s 50 day simple moving average is $35.76 and its 200-day simple moving average is $31.43.

Institutional Trading of AtriCure

Hedge funds and other institutional investors have recently made changes to their positions in the business. PDT Partners LLC grew its position in AtriCure by 65.9% in the fourth quarter. PDT Partners LLC now owns 39,327 shares of the medical device company’s stock worth $1,202,000 after buying an additional 15,626 shares during the last quarter. First Light Asset Management LLC boosted its stake in shares of AtriCure by 5.6% during the 4th quarter. First Light Asset Management LLC now owns 1,969,221 shares of the medical device company’s stock worth $60,179,000 after acquiring an additional 103,685 shares in the last quarter. Northern Trust Corp grew its holdings in shares of AtriCure by 11.6% in the 4th quarter. Northern Trust Corp now owns 483,607 shares of the medical device company’s stock worth $14,779,000 after acquiring an additional 50,153 shares during the last quarter. Johnson Financial Group Inc. raised its position in shares of AtriCure by 1,184.1% during the fourth quarter. Johnson Financial Group Inc. now owns 1,618 shares of the medical device company’s stock worth $49,000 after purchasing an additional 1,492 shares during the period. Finally, Boothbay Fund Management LLC purchased a new stake in shares of AtriCure during the fourth quarter valued at $231,000. 99.11% of the stock is currently owned by institutional investors.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.